Citation:D'Addario G, Pintilie M, Leighl NB, Feld R, Cerny T, Shepherd FA 2005

From Cancer Guidelines Wiki

Citation


D'Addario G, Pintilie M, Leighl NB, Feld R, Cerny T, Shepherd FA. Platinum-based versus non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a meta-analysis of the published literature. J Clin Oncol 2005 May 1;23(13):2926-36 Available from: http://www.ncbi.nlm.nih.gov/pubmed/15728229.



Critical appraisals

Critical appraisal linkClinical questionAssigned toStatus
D'Addario G, Pintilie M, Leighl NB, Feld R, Cerny T, Shepherd FA 2005What is the optimal systemic therapy for stage IV inoperable NSCLC?Assoc. Prof. Nick Pavlakiscompleted
D'Addario G, Pintilie M, Leighl NB, Feld R, Cerny T, Shepherd FA 2005 2What is the optimal first-line chemotherapy regimen in patients with stage IV inoperable NSCLC?Assoc. Prof. Nick Pavlakiscompleted
D'Addario G, Pintilie M, Leighl NB, Feld R, Cerny T, Shepherd FA 2005 3Is monotherapy with new third generation (3G) agents as effective as platinum combination therapy for treatment of stage IV inoperable NSCLC?Assoc. Prof. Nick Pavlakiscompleted
D'Addario G, Pintilie M, Leighl NB, Feld R, Cerny T, Shepherd FA 2005 4Are non-platinum doublet chemotherapy regimens as effective as platinum doublet regimens for treatment of stage IV inoperable NSCLC?Assoc. Prof. Nick Pavlakiscompleted

Compare quality appraisals for each clinical question

  • [[Clinical question:What is the optimal systemic therapy for stage IV inoperable NSCLC?|
    Invalid title «<span class="smw-format list-format "><span class="smw-row"><span class="smw-field"><span class="smw-value">Clinical question:What is the optimal systemic therapy for stage IV inoperable NSCLC?</span></span></span>»
    ]] (compare critical appraisals)
  • [[Clinical question:What is the optimal first-line chemotherapy regimen in patients with stage IV inoperable NSCLC?|
    Invalid title «<span class="smw-row"><span class="smw-field"><span class="smw-value">Clinical question:What is the optimal first-line chemotherapy regimen in patients with stage IV inoperable NSCLC?</span></span></span>»
    ]] (compare critical appraisals)
  • [[Clinical question:Is monotherapy with new third generation (3G) agents as effective as platinum combination therapy for treatment of stage IV inoperable NSCLC?|
    Invalid title «<span class="smw-row"><span class="smw-field"><span class="smw-value">Clinical question:Is monotherapy with new third generation (3G) agents as effective as platinum combination therapy for treatment of stage IV inoperable NSCLC?</span></span></span>»
    ]] (compare critical appraisals)
  • [[Clinical question:Are non-platinum doublet chemotherapy regimens as effective as platinum doublet regimens for treatment of stage IV inoperable NSCLC?|
    Invalid title «<span class="smw-row"><span class="smw-field"><span class="smw-value">Clinical question:Are non-platinum doublet chemotherapy regimens as effective as platinum doublet regimens for treatment of stage IV inoperable NSCLC?</span></span></span></span>»
    ]] (compare critical appraisals)

Cited by

  1. Are non-platinum doublet chemotherapy regimens as effective as platinum doublet regimens for treatment of stage IV inoperable NSCLC?
  2. What is the optimal systemic therapy for stage IV inoperable NSCLC?
Retrieved from "https://wiki.cancer.org.au/australiawiki/index.php?title=Citation:D%27Addario_G,_Pintilie_M,_Leighl_NB,_Feld_R,_Cerny_T,_Shepherd_FA_2005&oldid=21621"